Overview

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis

Status:
Unknown status
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This is a single blind phase 2a study to evaluate the safety, tolerability, pharmacokinetics, and exploratory efficacy of nimacimab in patients with diabetic gastroparesis.
Phase:
Phase 2
Details
Lead Sponsor:
Bird Rock Bio, Inc.